The emergency use of Johnson & Johnson’s single-dose corona vaccine has been approved in the country. Union Health Minister Mansukh Mandaviya has given this information by tweeting. This will be the fourth corona vaccine to be available in the country. Serum Institute’s Kovishield (Oxford-AstraZeneca), Bharat Biotech’s Covaccine and Dr. Reddy’s Sputnik V (Russia vaccine) are already available.
After getting approval for emergency use of this vaccine in India, Johnson & Johnson Company has also given its response. A Johnson & Johnson India spokesperson wrote on Twitter, “We are pleased to announce that on 7 August 2021, the Government of India issued an Emergency Use Authorization (EUA) for the Johnson & Johnson COVID19 Single-Dose Vaccine in India, To prevent COVID in persons 18 years of age and above.
How will Johnson & Johnson produce this vaccine in India, what will be its cost? Not much information has been given about this. But the company has definitely said that biological e will play an important role in its global supply. Healthcare giant Johnson & Johnson had applied for approval for the emergency use of its corona vaccine in India. The company gave this information on Friday. This vaccine of Johnson is of one dose. At present, a two-dose vaccine is being administered in India.
What type of vaccine?
The J&J vaccine is a non-replicating viral vector vaccine. This means that the genetic material inside the vaccine will not copy itself inside the body. This is necessary because when the virus enters the body, it starts making copies of itself, which spreads the infection.
At what temperature is it kept?
This vaccine can be stored between 2 to 8 degree temperature. Unopened vials can be kept between 9 degree to 25 degree temperature for 12 hours.
On Monday, Johnson & Johnson Company said that it is committed to bring its single dose corona vaccine to India and talks are going on with the government regarding this. A spokesperson for Johnson & Johnson India issued a statement, “On August 5, 2021, Johnson & Johnson Pvt. Ltd. has applied to the Government of India for emergency use of its single dose vaccine.
The company has termed it as an important step towards bringing the single dose vaccine to India. Johnson & Johnson has tied up with Biological E Limited for this. The company said that permission for emergency use was sought based on the safety and effectiveness data of Phase III clinical trials. In this trial, this vaccine has been found to be 85 percent effective in preventing serious cases.